139 related articles for article (PubMed ID: 2264019)
1. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats.
Diness V; Lund-Hansen T; Hedner U
Thromb Res; 1990 Sep; 59(6):921-9. PubMed ID: 2264019
[TBL] [Abstract][Full Text] [Related]
2. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa.
Kaku S; Suzuki M; Saitoh M; Funatsu T; Uemura T; Suzuki K; Iwatsuki Y; Kawasaki T
Thromb Res; 2013 May; 131(5):450-6. PubMed ID: 23591155
[TBL] [Abstract][Full Text] [Related]
3. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects.
Skolnick BE; Mathews DR; Khutoryansky NM; Pusateri AE; Carr ME
Blood; 2010 Aug; 116(5):693-701. PubMed ID: 20385794
[TBL] [Abstract][Full Text] [Related]
4. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor.
Telgt DS; Macik BG; McCord DM; Monroe DM; Roberts HR
Thromb Res; 1989 Dec; 56(5):603-9. PubMed ID: 2626745
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
[TBL] [Abstract][Full Text] [Related]
6. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
Dickneite G
Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841
[TBL] [Abstract][Full Text] [Related]
7. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
Le Saché F; Le Bonniec B; Gaussem P; Dizier B; Tagzirt M; Godier A; Emmerich J; Samama CM
Br J Anaesth; 2012 Apr; 108(4):586-93. PubMed ID: 22258204
[TBL] [Abstract][Full Text] [Related]
8. Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro.
Darlington DN; Delgado AV; Kheirabadi BS; Fedyk CG; Scherer MR; Pusateri AE; Wade CE; Cap AP; Holcomb JB; Dubick MA
J Trauma; 2011 Nov; 71(5):1152-63. PubMed ID: 21610535
[TBL] [Abstract][Full Text] [Related]
9. On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation.
Gerotziafas GT; Zervas K; Arzoglou P; Karavaggeli E; Parashou S; Van Dreden P; Christakis J; Samama MM
Br J Haematol; 2002 Jun; 117(3):705-8. PubMed ID: 12028045
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
11. Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans.
Schut AM; Hyseni A; Adelmeijer J; Meijers JC; De Groot PG; Lisman T
Thromb Haemost; 2014 Aug; 112(2):304-10. PubMed ID: 24695949
[TBL] [Abstract][Full Text] [Related]
12. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
Tanaka KA; Szlam F; Dickneite G; Levy JH
Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
[TBL] [Abstract][Full Text] [Related]
13. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Keeney M; Allan DS; Lohmann RC; Yee IH
Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model.
Diness V; Bregengaard C; Erhardtsen E; Hedner U
Thromb Res; 1992 Jul; 67(2):233-41. PubMed ID: 1440525
[TBL] [Abstract][Full Text] [Related]
15. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model.
Hedner U; Ljundberg J; Lund-Hansen T
Blood Coagul Fibrinolysis; 1990 Jun; 1(2):145-51. PubMed ID: 2130926
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of rFVIIa, 4-factor PCC, and a rFVIIa and 3-factor PCC combination in improving bleeding outcomes in the warfarin and non-warfarin patient.
DeLoughery E; Avery B; DeLoughery TG
Am J Hematol; 2016 Jul; 91(7):705-8. PubMed ID: 27074566
[TBL] [Abstract][Full Text] [Related]
18. In vitro effect of activated recombinant factor VII (rFVIIa) on coagulation properties of human blood at hypothermic temperatures.
Kheirabadi BS; Delgado AV; Dubick MA; Scherer MR; Fedyk CG; Holcomb JB; Pusateri AE
J Trauma; 2007 Nov; 63(5):1079-86. PubMed ID: 17993954
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates.
Sadeghi N; Iacobelli M; Vaziri B; Kahn D; Hoppensteadt D; Guler N; Fareed J
Clin Appl Thromb Hemost; 2017 Apr; 23(3):211-220. PubMed ID: 27553841
[TBL] [Abstract][Full Text] [Related]
20. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries.
Martinowitz U; Holcomb JB; Pusateri AE; Stein M; Onaca N; Freidman M; Macaitis JM; Castel D; Hedner U; Hess JR
J Trauma; 2001 Apr; 50(4):721-9. PubMed ID: 11303171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
